Marks’s Nanopatch™ idea was to offer a needle-free method of drug delivery that could be widely used and increase vaccine efficacy.
In 2011 UniQuest, the University of Queensland’s commercialisation company, helped Mark found Vaxxas to advance the possibility of Nanopatch™ becoming a clinically-proven product.
Today, Vaxxas and Mark are getting closer to making that idea a reality by raising £12.7 million of funding for a series of clinical programs and the development of a pipeline of new vaccine products for major diseases.
In principle, their work could result in future chemical factories consisting of colonies of genetically engineered bacteria.
The Wyss Institute team has been able to trick the bacteria into self–eliminating the cells that are not high–output performers, ridding the entire process of the need for human and technological monitoring to make sure the bacteria are producing efficiently, and therefore hugely reducing the overall timescale of chemical production. Continue reading Bacteria on a factory scale (Day 233)